Advertisement
U.S. markets open in 8 hours 40 minutes
  • S&P Futures

    5,093.00
    -8.50 (-0.17%)
     
  • Dow Futures

    39,145.00
    -44.00 (-0.11%)
     
  • Nasdaq Futures

    17,958.75
    -32.25 (-0.18%)
     
  • Russell 2000 Futures

    2,016.60
    -3.90 (-0.19%)
     
  • Crude Oil

    76.11
    -0.38 (-0.50%)
     
  • Gold

    2,042.30
    -7.10 (-0.35%)
     
  • Silver

    22.84
    -0.14 (-0.62%)
     
  • EUR/USD

    1.0826
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    4.2600
    0.0000 (0.00%)
     
  • Vix

    13.75
    -0.79 (-5.43%)
     
  • GBP/USD

    1.2668
    -0.0004 (-0.03%)
     
  • USD/JPY

    150.3690
    -0.0710 (-0.05%)
     
  • Bitcoin USD

    51,593.21
    -98.11 (-0.19%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,236.14
    +137.44 (+0.35%)
     

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vera Therapeutics
Vera Therapeutics

BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 6th Annual Guggenheim Biotechnology Conference, which is taking place in New York on February 7th and 8th.

Fireside Chat Details:

Date:

Wednesday, February 7th

Time:

2:00 PM ET

 

 

The management team will be available for one-on-one investor meetings. Please contact your Guggenheim representative to request a meeting.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Mari Purpura
LifeSci Advisors
mpurpura@lifesciadvisors.com


Advertisement